systolic BP <140 mm Hg) or the ACCORD lipid trial (intensive lipid control using fenofibrate 160 mg/d or standard lipid control using placebo). 14, 19 Because of the increased risk of all-cause and cardiovascular mortality, intensive glycemic therapy was discontinued on February 6, 2008, 14 and the participants were switched to the standard regimen and followed up until December 31, 2010. From participating sites, all surviving ACCORD participants were subsequently offered the opportunity to participate in the ACCORDION study, during which cardiovascular and other health-related outcomes were recorded. 15 No active therapies were provided during this follow-up period. All participants provided written informed consent to participate in ACCORDION. In the present study, patients with missing information regarding thiazide use were excluded (n=27). In addition, patients with missing information regarding potential confounders were excluded from the main analyses (n=213), which resulted in a sample of 10 011. The Institutional Review Board of the National Center for Global Health and Medicine approved the present study. The National Heart, Lung, and Blood Institute approved the use of ACCORD and ACCORDION data.
Primary and Secondary Outcomes
The primary outcome was major adverse cardiovascular events (MACE), which was a composite end point including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Secondary outcomes were cardiovascular death, major coronary heart disease, and stroke. All-cause death and congestive heart failure were also evaluated. Cardiovascular death was defined as presumed cardiovascular death, unexpected death, or death from myocardial infarction, congestive heart failure, arrhythmia, stroke, or other cardiovascular diseases including pulmonary emboli and abdominal aortic aneurysm rupture. 16 prespecified. The ACCORD participants were followed up at least every 4 months to monitor study outcomes 14 and were followed up for a maximum of 13 years in the present study. The occurrence of cardiovascular outcomes and deaths was ascertained during 4 telephone calls and 3 clinic visits.
Potential Confounders
Potential confounders included age, sex, race/ethnicity, educational attainment, smoking status, BMI, duration of diabetes mellitus, hypertension, dyslipidemia, history of cardiovascular disease (coronary artery disease, stroke, and congestive heart failure), use of medications (insulin, metformin, thiazolidinedione, other antihyperglycemic medications, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, calcium channel blockers, β-blockers, loop diuretics, statins, aspirin, and oral anticoagulants), glycated hemoglobin, low-and high-density lipoprotein cholesterol, systolic and diastolic BP, estimated glomerular filtration rate, and the glycemic, BP, and lipid control strategy assigned in the ACCORD trial.
Statistical Analyses
Patients were divided into 2 groups depending on use of thiazides or no use of thiazides. Further, the patients were stratified into 3 subgroups: all patients, patients receiving standard BP control, and patients receiving intensive BP control. Demographic data were represented as proportions or means±SDs. Comparisons were performed between patients taking and not taking thiazides. Categorical variables were compared using χ 2 tests, and continuous variables were compared using t tests. Kaplan-Meier survival curves were constructed for primary and secondary outcomes, and the rate of each event was calculated in patients taking and not taking thiazides. Unadjusted and adjusted hazard ratios (HRs) for primary and secondary outcomes with 95% CIs were calculated using Cox proportional hazard models to compare time to occurrence of outcome events. We adjusted for potential confounders including age, sex, race/ethnicity, educational attainment, smoking status, BMI, duration of diabetes mellitus, hypertension, dyslipidemia, history of cardiovascular disease (coronary artery disease, stroke, and congestive heart failure), use of medications (insulin, metformin, thiazolidinedione, other antihyperglycemic medications, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, calcium channel blockers, β-blockers, loop diuretics, statins, aspirin, and oral anticoagulants), glycated hemoglobin, low-and high-density lipoprotein cholesterol, systolic and diastolic BP, estimated glomerular filtration rate, and the glycemic, BP, and lipid control strategy assigned in the ACCORD trial (BP and lipid control strategy were excluded from the multivariable analyses for participants in the ACCORD BP trial). We performed an additional analysis, considering the use of thiazides as a time-varying variable in an extended Cox model. 20 To confirm the results, additional analyses using propensity score (PS) 1:1 nearest neighbor matching without replacement were performed 21 separately in all patients, patients receiving standard BP control, and patients receiving intensive BP control. The PS was calculated using a logistic regression model that included use of thiazides as the outcome variable and the potential confounders related to the indication of thiazides as predictors. Standardized differences of ≤0.1 were considered negligible. The association between use of thiazides and cardiovascular events was also analyzed in the following subgroups: age (<65 or ≥65 . Cardiovascular disease was defined as myocardial infarction, angina pectoris, coronary revascularization including coronary artery bypass grafting or percutaneous coronary intervention, stroke, or other revascularization procedures such as carotid artery revascularization and peripheral artery revascularization. We tested effect modification by evaluating interactions between thiazide use and the subgroups.
In addition, we assessed the visit-to-visit BP variability in patients taking and not taking thiazides. Visit-to-visit BP variability was defined as the coefficient of variation (calculated as SD/mean BP×100%) of systolic BP at 4, 8, and 12 months. 22 Further, considering the effects of thiazides on cardiovascular events, we assessed the associations between BP control strategy and cardiovascular events separately in patients taking and not taking thiazides.
All statistical analyses were conducted using the software Stata (version 14.1; Stata Corp, College Station, TX). A P of <0.05 was considered statistically significant in all tests.
Results

Baseline Characteristics
The present study included 10 011 type 2 diabetic patients: 7242 patients not taking thiazides and 2769 patients taking thiazides. Patient characteristics are presented in Table 1 . Among all the patients, thiazide use was associated with older age, higher proportion of women, lower proportion of white, lower current smoking rate, greater BMI, more complications due to hypertension and stroke, and fewer complications due to coronary artery disease and heart failure. In terms of antihypertensive medications, thiazide use in all patients was associated with more frequent use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, calcium channel blockers, and β-blockers but less frequent use of loop diuretics. In patients receiving standard or intensive BP control, thiazide use was associated with more frequent use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers but less frequent use of loop diuretics. Mean (SD) systolic BP at baseline in patients taking and not taking thiazides was 137.2 (16.9) and 135.7 (16.3) mm Hg, respectively, and diastolic BP was 74.8 (10.4) and 74.6 (10.2) mm Hg, respectively. Similar baseline characteristics were observed in patients receiving standard (n=2315) or intensive (n=2311) BP control.
Primary and Secondary Outcomes
The overall mean (SD) follow-up period was 7.7 (3.3) years, and 1776 patients experienced MACE; specifically, in patients not taking and taking thiazides, respectively, the follow-up period was 7.7 (3.3) and 7.7 (3.1) years, and 1262 and 514 of them experienced MACE. Among all patients, the event rate (per 1000 person-years) for MACE in those taking and not taking thiazides was 24.2 and 22.5, respectively ( Table 2) . After multivariable adjustments, the risk of MACE was significantly higher in those taking thiazides than in those not taking thiazides (adjusted HR, 1.12 [95% CI, 1.01-1.25]; P=0.03; Table 2 ). The risk of MACE in patients receiving standard BP control did not differ significantly between those taking and not taking thiazides (adjusted HR, 1.09 [95% CI, 0.86-1.37]; P=0.47), whereas the risk of MACE in patients receiving intensive BP control was significantly higher in those taking thiazides than in those not taking thiazides (adjusted HR, 1.49 [95% CI, 1.18-1.88]; P<0.001). The risks of all-cause death, cardiovascular death, and major coronary events in all patients were not significantly different between those taking and not taking thiazides. However, the risk of stroke was significantly higher in patients taking thiazides than in those not taking thiazides (adjusted HR, 1.34 [95% CI, 1.10-1.63]; P=0.004). Among patients receiving standard BP control, the risks of all-cause death, cardiovascular death, major coronary events, and stroke did not differ significantly between those taking and not taking thiazides. Among patients receiving intensive BP control, the risks of all-cause death, cardiovascular death, and major coronary events were not significantly different between the 2 groups, whereas the risk of stroke was significantly higher in those taking thiazides than in those not taking thiazides (adjusted HR, 2.15 [95% CI, 1.47-3.32]; P<0.001). Analysis using a time-varying model showed significant associations between thiazide use and increased risk of stroke in patients receiving standard BP control (adjusted HR, 1.31 [95% CI, 1.03-1.67]; P=0.02) and in those receiving intensive BP control (adjusted HR, 1.73 [95% CI, 1.35-2.21]; P<0.001). Figure S1 in the online-only Data Supplement shows the association of thiazide use with the risk of MACE or stroke in each subgroup. In terms of risk of MACE ( Figure S1A ), there were no significant interactions between thiazide use and age (<65 or ≥65 years), sex (male or female), obesity (BMI <30 or ≥30 kg/ m 2 ), duration of diabetes mellitus (<10 or ≥10 years), history of cardiovascular disease (no history or history), glycated hemoglobin (<8% or ≥8%), systolic BP (<140 or ≥140 mm Hg), or diastolic BP (<80 or ≥80 mm Hg). Similarly, no significant interactions were detected in terms of stroke risk ( Figure S1B ).
The proportions of patients with systolic BP <100 mm Hg were not significantly different between patients taking and not taking thiazides at baseline (0.6% versus 0.8%; P=0.29) and on follow-up after 1 year (2.2% versus 2.2%; P=0.84) and 2 years (2.6% versus 2.5%; P=0.97). Patients taking and not taking thiazides had no significant differences in the mean (SD) coefficient of variation for standard BP control (5.7 
PS-Matched Analyses
The baseline characteristics of PS-matched patients taking (n=2620) and not taking (n=2620) thiazides are shown in Table S1 . The characteristics were well matched. Similarly, the characteristics of PS-matched patients receiving standard or intensive BP control were well matched between patients taking and not taking thiazides (Tables S2 and S3 ).
Kaplan-Meier survival curves for MACE, cardiovascular death, major coronary events, and stroke in the PS-matched patients are shown in Figure 1 . The risk of MACE was significantly higher in PS-matched patients taking thiazides than in those not taking thiazides (HR, 1.14 [95% CI, 1.00-1.29]; P=0.04). In addition, the risk of stroke was significantly higher in those taking thiazides than in those not taking thiazides (HR, 1.40 [95% CI, 1.10-1.77];
P=0.005). The risks of cardiovascular death and major coronary events were not significantly different between the 2 groups (HR for cardiovascular death, 1.11 [95% CI, 0.89-1.38]; P=0.34; and HR for major coronary events, 0.97 [95% CI, 0.85-1.10]; P=0.60). Among PS-matched patients receiving standard BP control, the risks of MACE, cardiovascular death, major coronary events, and stroke did not significantly differ between those taking and not taking thiazides ( Figure S2 ). However, among PS-matched patients receiving intensive BP control, the risks of cardiovascular death and major coronary events were not significantly different, whereas the risks of MACE and stroke were significantly higher in those taking thiazides than in those not taking thiazides (HR for MACE, 1.63 [95% CI, 1.22-2.18]; P=0.001; and HR for stroke, 2.30 [95% CI, 1.36-3.89]; P=0.001; Figure 2) .
The risks of all-cause death and congestive heart failure were not significantly higher in patients taking thiazides than in those not taking thiazides within each PS-matched patient group (Figures S3 through S5 ).
Effects of Intensive BP Control in Type 2 Diabetic Patients Taking Thiazides or Not Taking Thiazides
Changes in BP among patients receiving standard or intensive BP control are shown in Figure S6 . In patients taking thiazides and in those not taking thiazides, systolic and diastolic BP were significantly lower in patients receiving intensive BP control than in those receiving standard BP control. Although the difference between patients receiving standard and intensive BP control was reduced after the intervention in the ACCORD BP study was stopped, some difference remained. Kaplan-Meier survival curves for MACE and stroke in the standard or intensive BP control group in patients taking thiazides or not taking thiazides are shown in Figure 3 . Among patients not taking thiazides, intensive BP control resulted in lower risk of MACE than standard BP control (HR, 0.84 [95% CI, 0.70-0.99]; P=0.03; Figure 3A ). In contrast, among patients taking thiazides, the risk of MACE was not significantly lower in the intensive BP control group than in the standard BP control group (HR, 1.11 [95% CI, 0.86-1.42]; P=0.42; Figure 3B) . Similarly, the risk of stroke in patients not taking thiazides was significantly lower in the intensive BP control group (HR, 0.69 [95% CI, 0.50-0.97]; P=0.03; Figure 3C ), whereas that in patients taking thiazides did not differ significantly between the 2 groups (HR, 1.17 [95% CI, 0.78-1.75]; P=0.44; Figure 3D ).
Discussion
The present study demonstrated that the use of thiazides was associated with increased risk of MACE, particularly stroke, in type 2 diabetic patients. The difference in the MACE risk was possibly due to the difference in the stroke risk between patients taking and not taking thiazides because the incidence of major coronary events and cardiovascular mortality was similar between the 2 groups. In addition, the risk of cardiovascular events in patients receiving standard BP control was not significantly different between those taking and not taking thiazides, whereas the risks of MACE and stroke in patients receiving intensive BP control were significantly higher in those taking thiazides than in those not taking thiazides. Similar associations were observed in the analyses using PS matching. There were no significant interactions between the use of thiazides and clinically important variables. Intensive BP control in patients taking thiazides did not reduce cardiovascular risk, whereas that in patients not taking thiazides resulted in decreased risks of MACE and stroke. Thiazide use in hypertensive patients is recommended by many guidelines. 5,23,24 However, 2 or 3 decades ago, several studies reported that the use of thiazides in patients with diabetes mellitus lowers BP and is associated with reduced risk of cardiovascular events. [10] [11] [12] In addition, even in previous trials reporting associations between thiazide use and decreased risk of cardiovascular events, the cardiovascular benefits might have been derived from lowering BP. [6] [7] [8] [9] Thus, there have been few studies assessing the effects of thiazides on cardiovascular events in patients with well-controlled BP. Several previous trials have shown that thiazides were potentially inferior, when compared with other antihypertensive classes. [25] [26] [27] The ANBP2 (Second Australian National Blood Pressure Study) demonstrated that angiotensin-converting enzyme inhibitors in older subjects, particularly men, appeared to improve the outcomes than treatment with diuretic agents, despite similar reductions of BP. 25 The ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm) reported that compared with atenolol adding thiazide as required, the amlodipine adding perindopril as required prevented more major cardiovascular events and induced less diabetes mellitus. 26 The ACCOMPLISH trial (Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension) showed that combination treatment with benazepril plus amlodipine was superior to treatment with benazepril plus hydrochlorothiazide in reducing the risk of cardiovascular events and death among high-risk patients with hypertension. 27 Although thiazides inhibit sodium transport in the distal convoluted tubule, the mechanisms responsible for decline in BP remain unclear. The hypotensive response is partially mediated by a modest reduction in plasma volume and cardiac output. 28 The present study indicated that the use of thiazides in type 2 diabetic patients, particularly those receiving intensive BP control, was associated with increased risk of stroke. Considering that the present study included many type 2 diabetic patients with atherosclerosis, a possible explanation is that reduction in plasma volume and cardiac output due to thiazides in patients with atherosclerosis and low BP might result in cerebral blood hypoperfusion, leading to stroke events. Another possible explanation is that hypokalemia in patients with thiazides might induce arrhythmias such as atrial fibrillation. 29, 30 Previous studies suggested that a relatively high visit-to-visit BP variability was associated with higher risk of stroke. 31, 32 In the present study, although the visit-to-visit BP variability was not significantly different between patients taking and not taking thiazides, further analyses were required to determine the associations between thiazide use and visit-to-visit BP variations. Because the reason for the increased risk of stroke remains unclear, further studies are warranted to assess the efficacy and safety of thiazides in patients receiving intensive BP control.
The ACCORD BP study demonstrated that, compared with standard BP control, intensive BP control in high-risk patients with type 2 diabetes mellitus showed no significant reduction in the composite outcome of fatal and nonfatal major cardiovascular events. 33 Additionally, previous studies have suggested that low BP, especially low diastolic BP, in high-risk patients was associated with increased risks of cardiovascular events and renal failure. 34, 35 In contrast, SPRINT (Systolic Blood Pressure Intervention Trial) reported that compared with standard BP control, intensive BP control decreased the incidence of cardiovascular events in high-risk patients without diabetes mellitus or a prior history of stroke. 36 These differing results between the ACCORD BP and the SPRINT studies might be attributed to the inclusion of different subjects, different BP measurements, and different composite outcomes of cardiovascular events. However, recent studies suggested that intensive BP control in type 2 diabetic patients may reduce incidence of cardiovascular events. [37] [38] [39] In the present study, although the BP was significantly lower in patients receiving intensive BP control than in those receiving standard BP control, regardless of thiazide use, the beneficial effects of intensive BP control were observed only in patients not taking thiazides. Considering the results of the present study using data from the ACCORD BP study, an intensive BP control strategy may be beneficial in type 2 diabetic patients under specific conditions.
The present study has several limitations. First, it was an observational study using data from the ACCORD and ACCORDION studies. Many baseline characteristics, including antihypertensive medications, were different between patients taking and not taking thiazides. Particularly, thiazide use was associated with older age, higher proportion of black race, and greater BMI, which might have affected the results of this study. Although the various analyses, including multivariable adjustment and PS matching, suggested the risks associated with thiazide use in type 2 diabetic patients with low BP, there might have been residual bias including unmeasured and unknown confounders, even after adjustment, due to the uncontrolled nature of observational studies. Second, it is unknown whether the patients took thiazides during follow-up. The various analyses, including the fixed covariate Cox model and the time-dependent Cox model that used thiazides as a time-varying variable, found similar associations between thiazide use and increased risk of stroke. However, the results of this study should be validated using other large-scale dataset with detailed information, such as the United Kingdom Clinical Practice Research Datalink dataset. Third, there was no information regarding the doses and types of thiazides, such as chlorthalidone, indapamide, and hydrochlorothiazide. Thiazides are a heterogeneous group of drugs, and different effects have been documented between thiazide-type and thiazide-like diuretics. 40 It would have been important to identify the types of thiazides that were associated with increased risk of stroke. In addition, because of the lack of information regarding orthostatic hypotension and syncope, we could not assess these adverse events. Further studies about the association between thiazide use and stroke in patients with relatively low BP are required, using data with detailed information, including the doses and types of thiazides and adverse events. Moreover, the associations between other diuretics and stroke in patients with relatively low BP should be assessed in future studies. Fourth, the ACCORD and ACCORDION participants were high-risk type 2 diabetic patients. Therefore, it remains unclear whether similar results would be observed in low-risk type 2 diabetic patients or nondiabetic patients. Fifth, diabetes mellitus management strategies have changed since the ACCORD study was initiated. Therefore, new randomized controlled trials or more recent cohorts are needed to validate the results of the present study.
In conclusion, the present study demonstrated that the use of thiazides was associated with an increased risk of stroke in type 2 diabetic patients, specifically those receiving intensive BP control. Further studies are warranted to assess the association between thiazide use and stroke in type 2 diabetic patients with relatively low BP.
Perspectives
Recent systematic reviews have concluded that available evidence supports antihypertensive drug treatment in type 2 diabetic patients with hypertension, using any major classes including thiazides. In fact, 2 or 3 decades ago, several studies had demonstrated that the use of thiazides was beneficial in hypertensive patients. However, most of these studies were conducted in patients with moderate-to-severe high BP. In addition, because some study patients taking thiazides had a greater reduction in BP compared with those taking placebo or other antihypertensive agents, it remains unknown whether the benefits were derived from lowering BP or the use of thiazides. Overall, evidence regarding the efficacy and safety of thiazides in patients with well-controlled and relatively low BP is lacking. In the present study, thiazide use was associated with an increased risk of stroke in type 2 diabetic patients, specifically those receiving intensive BP control. Our findings indicate that thiazide use may increase the risk of stroke in type 2 diabetic patients with relatively low BP.
